Over 90% reduced death risk with treatment in subgroup for ultra rare TK2d disease

New data published in Brain Communications offers a strong picture of how devastating thymidine kinase 2 deficiency (TK2d) can be without treatment - and how vital earlier diagnosis and treatment are in potentially changing the course of disease.

One manuscript examines the safety and efficacy of Belgian drugmaker UCB’s (Euronext: UCB) Kygevvi (doxecitine and doxribtimine) in treating the condition, and the other highlights the progressive disease burden in untreated patients using the largest published patient dataset to date.